1AQ1 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE |
1B38 | A: | HUMAN CYCLIN-DEPENDENT KINASE 2 |
1B39 | A: | HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 |
1BUH | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1 |
1CKP | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B |
1DI8 | A: | THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE |
1DM2 | A: | HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE |
1E1V | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 |
1E1X | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 |
1E9H | A:; C: | THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND |
1F5Q | A:; C: | CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2 |
1FIN | A:; C: | CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX |
1FQ1 | B: | CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2 |
1FVT | A: | THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR |
1FVV | A:; C: | THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR |
1G5S | A: | CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717 |
1GIH | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR |
1GII | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR |
1GIJ | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR |
1GY3 | A:; C: | PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE |
1GZ8 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL-2'-OXO)BUTOXYPURINE |
1H00 | A: | CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR |
1H01 | A: | CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR |
1H07 | A: | CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR |
1H08 | A: | CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR |
1H0V | A: | HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5'-YL]METHOXYPURINE |
1H0W | A: | HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE |
1H1P | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 |
1H1Q | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 |
1H1R | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 |
1H1S | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 |
1H24 | A:; C: | CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F |
1H25 | A:; C: | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN |
1H26 | A:; C: | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 |
1H27 | A:; C: | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 |
1H28 | A:; C: | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 |
1HCK | A: | HUMAN CYCLIN-DEPENDENT KINASE 2 |
1HCL | A: | HUMAN CYCLIN-DEPENDENT KINASE 2 |
1JST | A:; C: | PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A |
1JSU | A: | P27(KIP1)/CYCLIN A/CDK2 COMPLEX |
1JSV | A: | THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE |
1JVP | P: | CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365 |
1KE5 | A: | CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE |
1KE6 | A: | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE |
1KE7 | A: | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE |
1KE8 | A: | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE |
1KE9 | A: | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE |
1OGU | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR |
1OI9 | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
1OIQ | A: | IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION |
1OIR | A: | IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION |
1OIT | A: | IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION |
1OIU | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
1OIY | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
1OKV | A:; C: | CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2 |
1OKW | A:; C: | CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2 |
1OL1 | A:; C: | CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2 |
1OL2 | A:; C: | CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2 |
1P2A | A: | THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR |
1P5E | A:; C: | THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS) |
1PF8 | A: | CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR |
1PKD | A:; C: | THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A |
1PW2 | A: | APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 |
1PXI | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2-YLAMINE |
1PXJ | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE |
1PXK | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'-HYDROXYIMINOFORMAMIDE |
1PXL | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE |
1PXM | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL |
1PXN | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL |
1PXO | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE |
1PXP | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE |
1PYE | A: | CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR |
1QMZ | A:; C: | PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX |
1R78 | A: | CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR |
1URC | A:; C: | CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY |
1URW | A: | CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE |
1V1K | A: | CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR |
1VYW | A:; C: | STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 |
1VYZ | A: | STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 |
1W0X | C: | CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE. |
1W8C | A: | CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2 |
1W98 | A: | THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E |
1WCC | A: | SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY |
1Y8Y | A: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1, 5-A]PYRIMIDINE INHIBITOR |
1Y91 | A: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1, 5-A]PYRIMIDINE INHIBITOR |
1YKR | A: | CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR |
2A0C | X: | HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR |
2A4L | A: | HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE |
2B52 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 |
2B53 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 |
2B54 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN-232305 |
2B55 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312 |
2BHE | A: | HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE |
2BHH | A: | HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE |
2BTR | A: | STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 |
2BTS | A: | STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 |
2C5N | A:; C: | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5O | A:; C: | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5V | A:; C: | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5X | A:; C: | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5Y | A: | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C68 | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C69 | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C6I | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C6K | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C6L | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C6M | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C6O | A: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2C6T | A:; C: | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2CCH | A:; C: | THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE |
2CCI | A:; C: | CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 |
2CJM | A:; C: | MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE |
2CLX | A: | 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS |
2DS1 | A: | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR |
2DUV | A: | STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES |
2EXM | A: | HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE |
2FVD | A: | CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR |
2G9X | A:; C: | STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271 |
2I40 | A:; C: | CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR |
2IW6 | A:1-295; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
2IW8 | A:1-297 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR |
2IW9 | A:; C: | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
2J9M | A: | CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE |
2JGZ | A: | CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B |
2R3F | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3G | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3H | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3I | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3J | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3K | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3L | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3M | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3N | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3O | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3P | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3Q | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R3R | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
2R64 | A: | CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2 |
2UUE | A:; C: | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
2UZB | A:; C: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZD | A:; C: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZE | A:; C: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZL | A:; C: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZN | A: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZO | A: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2V0D | A: | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2V22 | A:; C: | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
2VTA | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTH | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN |
2VTI | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTJ | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTL | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTM | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTN | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTO | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTP | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTQ | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTR | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTS | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VTT | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VU3 | A: | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
2VV9 | A: | CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE |
2W05 | A: | STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B |
2W06 | A: | STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C |
2W17 | A: | CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B |
2W1H | A: | FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY |
2WEV | A:; C: | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2WFY | A:; C: | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2WHB | A:; C: | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2WMA | A:; C: | STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A |
2WMB | A:; C: | STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A |
2X1N | A:; C: | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2XMY | A: | DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS |
2XNB | A: | DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS |
3BHT | A:; C: | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3 |
3BHU | A:; C: | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5 |
3BHV | A:; C: | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B |
3DDP | A:; C: | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8 |
3DDQ | A:; C: | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE |
3DOG | A:; C: | STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1 |
3EID | A:; C: | CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR |
3EZR | A: | CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE |
3EZV | A: | CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE |
3F5X | A:; C: | CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE |
3FZ1 | A: | CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2) |
3IG7 | A: | NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2 |
3IGG | A: | NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2 |
3LE6 | A: | THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR |
3LFN | A: | CRYSTAL STRUCTURE OF CDK2 WITH SAR57, AN AMINOINDAZOLE TYPE INHIBITOR |
3LFQ | A: | CRYSTAL STRUCTURE OF CDK2 WITH SAR60, AN AMINOINDAZOLE TYPE INHIBITOR |
3LFS | A: | CRYSTAL STRUCTURE OF CDK2 WITH SAR37, AN AMINOINDAZOLE TYPE INHIBITOR |
3MY5 | A:; C: | CDK2/CYCLINA IN COMPLEX WITH DRB |
3NS9 | A: | CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194 |
3PJ8 | A: | STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[4,3-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE. |
3PXF | A: | CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE |
3PXQ | A: | CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE |
3PXR | A: | APO CDK2 CRYSTALLIZED FROM JEFFAMINE |
3PXY | A: | CDK2 IN COMPLEX WITH INHIBITOR JWS648 |
3PXZ | A: | CDK2 TERNARY COMPLEX WITH JWS648 AND ANS |
3PY0 | A: | CDK2 IN COMPLEX WITH INHIBITOR SU9516 |
3PY1 | A: | CDK2 TERNARY COMPLEX WITH SU9516 AND ANS |
3QHR | A:; C: | STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC |
3QHW | A:; C: | STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC |
3QL8 | A: | CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260 |
3QQF | A: | CDK2 IN COMPLEX WITH INHIBITOR L1 |
3QQG | A: | CDK2 IN COMPLEX WITH INHIBITOR L2-5 |
3QQH | A: | CDK2 IN COMPLEX WITH INHIBITOR L2-2 |
3QQJ | A: | CDK2 IN COMPLEX WITH INHIBITOR L2 |
3QQK | A: | CDK2 IN COMPLEX WITH INHIBITOR L4 |
3QQL | A: | CDK2 IN COMPLEX WITH INHIBITOR L3 |
3QRT | A: | CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55 |
3QRU | A: | CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12 |
3QTQ | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-1-137 |
3QTR | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-1-148 |
3QTS | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-12 |
3QTU | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-132 |
3QTW | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-13 |
3QTX | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-35 |
3QTZ | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-36 |
3QU0 | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-38 |
3QWJ | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142 |
3QWK | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150 |
3QX2 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190 |
3QX4 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78 |
3QXO | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84 |
3QXP | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-3-89 |
3QZF | A: | CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52 |
3QZG | A: | CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76 |
3QZH | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124 |
3QZI | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126 |
3R1Q | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102 |
3R1S | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127 |
3R1Y | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134 |
3R28 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140 |
3R6X | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158 |
3R71 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162 |
3R73 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164 |
3R7E | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67 |
3R7I | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74 |
3R7U | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75 |
3R7V | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9 |
3R7Y | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88 |
3R83 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92 |
3R8L | A: | CDK2 IN COMPLEX WITH INHIBITOR L3-4 |
3R8M | A: | CDK2 IN COMPLEX WITH INHIBITOR L3-3 |
3R8P | A: | CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6 |
3R8U | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-1-132 |
3R8V | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-1-135 |
3R8Z | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-1-136 |
3R9D | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-135 |
3R9H | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-142 |
3R9N | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-21 |
3R9O | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-143 |
3RAH | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-22 |
3RAI | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160 |
3RAK | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-32 |
3RAL | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-34 |
3RJC | A: | CDK2 IN COMPLEX WITH INHIBITOR L4-12 |
3RK5 | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-72 |
3RK7 | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-71 |
3RK9 | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-74 |
3RKB | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-73 |
3RM6 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80 |
3RM7 | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91 |
3RMF | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-33 |
3RNI | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-3-86 |
3ROY | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154 |
3RPO | A: | CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156 |
3RPR | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-49 |
3RPV | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-88 |
3RPY | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-40 |
3RZB | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-23 |
3S00 | A: | CDK2 IN COMPLEX WITH INHIBITOR L4-14 |
3S0O | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-1-138 |
3S1H | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-2-39 |
3S2P | A: | CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND |
3SQQ | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-3-96 |
3SW4 | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR |
3SW7 | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR |
3TI1 | A: | CDK2 IN COMPLEX WITH SUNITINIB |
3TIY | A: | CDK2 IN COMPLEX WITH NSC 35676 |
3TIZ | A: | CDK2 IN COMPLEX WITH NSC 111848 |
3TNW | A:; C: | STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508 |
3ULI | A: | HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE |
3UNJ | A: | CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31 |
3UNK | A: | CDK2 IN COMPLEX WITH INHIBITOR YL5-083 |
3WBL | A: | CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR |
4ACM | A: | CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE |
4BCK | A:; C: | STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR |
4BCM | A:; C: | STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR |
4BCN | A:; C: | STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR |
4BCO | A:; C: | STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR |
4BCP | A:; C: | STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR |
4BCQ | A:; C: | STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR |
4BGH | A: | CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR |
4CFN | A:; C: | STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS. |
4CFW | A:; C: | STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS. |
4EK3 | A: | CRYSTAL STRUCTURE OF APO CDK2 |
4EK4 | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR |
4EK5 | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR |
4EK6 | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR |
4EK8 | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR |
4EOI | A:; C: | THR 160 PHOSPHORYLATED CDK2 K89D, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306 |
4EOJ | A:; C: | THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP |
4EOK | A:; C: | THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102 |
4EOL | A:; C: | THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306 |
4EOM | A:; C: | THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP |
4EON | A:; C: | THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306 |
4EOO | A:; C: | THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP |
4EOP | A:; C: | THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306 |
4EOQ | A:; C: | THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP |
4EOR | A:; C: | THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102 |
4EOS | A:; C: | THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306 |
4ERW | A: | CDK2 IN COMPLEX WITH STAUROSPORINE |
4EZ3 | A: | CDK2 IN COMPLEX WITH NSC 134199 |
4EZ7 | A: | CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONIC ACID |
4FKG | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR |
4FKI | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR |
4FKJ | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR |
4FKL | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR |
4FKO | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR |
4FKP | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKQ | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKR | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKS | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKT | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKU | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKV | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FKW | A: | CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR |
4FX3 | A:; C: | CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR |
4GCJ | A: | CDK2 IN COMPLEX WITH INHIBITOR RC-3-89 |
4I3Z | A:; C: | STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS |
4II5 | A:; C: | STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION |
4KD1 | A: | CDK2 IN COMPLEX WITH DINACICLIB |
4LYN | A: | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-1,3-OXAZOL-2-YL)METHYL)SULFANYL)-1,3-THIAZOL-2-YL)-2-PHENYLPROPANAMIDE |
4NJ3 | A: | MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE-BASED INHIBITOR |